Replicative aging and differentiation potential of human adipose tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine serum

References

• Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008;2:313–9.
   PubMed Web of Science ®Google Scholar
• Tolar J, Le Blanc K, Keating A, Blazar BR. Concise review. Hitting the right spot with mesenchymal stromal cells. Stem Cells. 2010;28:1446–55.
   PubMed Web of Science ®Google Scholar
• Levi B, Longaker MT. Adipose derived stromal cells for skeletal regenerative medicine. Stem Cells. 2011;29:576–82.
   PubMed Web of Science ®Google Scholar
• Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006;24:2582–91.
   PubMed Web of Science ®Google Scholar
• Madonna R, De Caterina R. Adipose tissue: a new source for cardiovascular repair. J Cardiovasc Med (Hagerstown). 2010;11:71–80.
   PubMedGoogle Scholar
• Garcia-Olmo D, Herreros D, Pascual M, Pascual I, De-La-Quintana P, Trebol J, . Treatment of enterocutaneous fistula in Crohn's disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. Int J Colorectal Dis. 2009;24:27–30.
   PubMed Web of Science ®Google Scholar
• Mannello F, Tonti GA. Concise review. No breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold! Stem Cells. 2007;25:1603–9.
   PubMed Web of Science ®Google Scholar
• Honn KV, Singley JA, Chavin W. Fetal bovine serum: a multivariate standard. Proc Soc Exp Biol Med. 1975;149:344–7.
   PubMed Web of Science ®Google Scholar
• Heiskanen A, Satomaa T, Tiitinen S, Laitinen A, Mannelin S, Impola U, . N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells. 2007;25:197–202.
   PubMed Web of Science ®Google Scholar
• Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica. 2007;92:1208–15.
   PubMed Web of Science ®Google Scholar
• Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E, . Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion. 2007;47:1436–46.
   PubMed Web of Science ®Google Scholar
• McKenna DH Jr, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S, . Good manufacturing practice production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion. 2007;47:520–8.
   PubMedGoogle Scholar
• Bieback K, Ha VA, Hecker A, Grassl M, Kinzebach S, Solz H, . Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. Tissue Eng Part A. 2010;16:3467–84.
   PubMed Web of Science ®Google Scholar
• Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, Strunk D, . Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells. 2009;27:2331–41.
   PubMed Web of Science ®Google Scholar
• Kocaoemer A, Kern S, Kluter H, Bieback K. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells. 2007;25:1270–8.
   PubMed Web of Science ®Google Scholar
• Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, . Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol. 2005;205:228–36.
   PubMed Web of Science ®Google Scholar
• Goldring CE, Duffy PA, Benvenisty N, Andrews PW, Ben-David U, Eakins R, . Assessing the safety of stem cell therapeutics. Cell Stem Cell. 2011;8:618–28.
   PubMed Web of Science ®Google Scholar
• Lepperdinger G, Brunauer R, Jamnig A, Laschober G, Kassem M. Controversial issue: is it safe to employ mesenchymal stem cells in cell-based therapies? Exp Gerontol. 2008;43:1018–23.
   PubMed Web of Science ®Google Scholar
• Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, . Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010;12:576–8.
   PubMed Web of Science ®Google Scholar
• Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, . Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007;67:9142–9.
   PubMed Web of Science ®Google Scholar
• Rubin H. Multistage carcinogenesis in cell culture. Dev Biol (Basel). 2001;106:61–6; discussion 7, 143–60.
   PubMedGoogle Scholar
• Vukicevic V, Jauch A, Dinger TC, Gebauer L, Hornich V, Bornstein SR, . Genetic instability and diminished differentiation capacity in long-term cultured mouse neurosphere cells. Mech Ageing Dev. 2010;131:124–32.
   PubMedGoogle Scholar
• Wieser M, Stadler G, Bohm E, Borth N, Katinger H, Grillari J, . Nuclear flow FISH: isolation of cell nuclei improves the determination of telomere lengths. Exp Gerontol. 2006;41:230–5.
   PubMedGoogle Scholar
• Breuninger S, Reidenbach S, Sauer CG, Strobel P, Pfitzenmaier J, Trojan L, . Desmosomal plakophilins in the prostate and prostatic adenocarcinomas: implications for diagnosis and tumor progression. Am J Pathol. 2010;176:2509–19.
   PubMed Web of Science ®Google Scholar
• Wuchter P, Boda-Heggemann J, Straub BK, Grund C, Kuhn C, Krause U, . Processus and recessus adhaerentes: giant adherens cell junction systems connect and attract human mesenchymal stem cells. Cell Tissue Res. 2007;328:499–514.
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.
   PubMed Web of Science ®Google Scholar
• Rojewski MT, Weber BM, Schrezenmeier H. Phenotypic characterization of mesenchymal stem cells from various tissues. Transfus Med Hemoth. 2008;35:168–84.
   PubMed Web of Science ®Google Scholar
• Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, . Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells. 2006;24:376–85.
   PubMed Web of Science ®Google Scholar
• Mutin M, Dignat-George F, Sampol J. Immunologic phenotype of cultured endothelial cells: quantitative analysis of cell surface molecules. Tissue Antigens. 1997;50:449–58.
   PubMedGoogle Scholar
• Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007;262:509–25.
   PubMed Web of Science ®Google Scholar
• Najar M, Raicevic G, Boufker HI, Fayyad-Kazan H, De Bruyn C, Meuleman N, . Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A. 2010;16:3537–46.
   PubMed Web of Science ®Google Scholar
• EMEA. Guideline on Human Cell-Based Medicinal Products. Official guideline of the European Medicines Agency: EMA, London, Great Britain, 2008 (Doc. Ref. EMEA/CHMP/410869/2006)
   Google Scholar
• Cholewa D, Stiehl T, Schellenberg A, Bokermann G, Joussen S, Koch C, . Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density. Cell Transplant. 2011;20:1409–22.
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Nakagawa H, Hosono N, Nakano K, Abe T, Boroevich KA, . Whole-genome sequencing and comprehensive variant analysis of a Japanese individual using massively parallel sequencing. Nat Genet. 2010;42:931–6.
   PubMedGoogle Scholar
• Peacocke M, Campisi J. Cellular senescence: a reflection of normal growth control, differentiation, or aging? J Cell Biochem. 1991;45:147–55.
   PubMed Web of Science ®Google Scholar
• Lee JS, Lee MO, Moon BH, Shim SH, Fornace AJ Jr, Cha HJ. Senescent growth arrest in mesenchymal stem cells is bypassed by Wip1-mediated downregulation of intrinsic stress signaling pathways. Stem Cells. 2009;27:1963–75.
   PubMedGoogle Scholar
• Heo JY, Jing K, Song KS, Seo KS, Park JH, Kim JS, . Downregulation of APE1/Ref-1 is involved in the senescence of mesenchymal stem cells. Stem Cells. 2009;27:1455–62.
   PubMedGoogle Scholar
• Molchadsky A, Shats I, Goldfinger N, Pevsner-Fischer M, Olson M, Rinon A, . p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One. 2008;3:e3707.
   Google Scholar
• Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem. 2002;277:29792–802.
   PubMed Web of Science ®Google Scholar
• Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, . Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood. 2010;115:1549–53.
   PubMed Web of Science ®Google Scholar
• Dahl JA, Duggal S, Coulston N, Millar D, Melki J, Shahdadfar A, . Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. Int J Dev Biol. 2008;52:1033–42.
   PubMed Web of Science ®Google Scholar
• Schellenberg A, Lin Q, Schuler H, Koch CM, Joussen S, Denecke B, . Replicative senescence of mesenchymal stem cells causes DNA-methylation changes which correlate with repressive histone marks. Aging (Albany NY). 2011; 3:873–88.
   PubMedGoogle Scholar
• Charbord P. Hemopoietic stem cells: analysis of some parameters critical for engraftment. Stem Cells. 1994;12:545–62.
   PubMedGoogle Scholar
• Rada T, Santos TC, Marques AP, Correlo VM, Frias AM, Castro AG, . Osteogenic differentiation of two distinct subpopulations of human adipose-derived stem cells: an in vitro and in vivo study. J Tissue Eng Regen Med. 2012;6:1–11.
   PubMed Web of Science ®Google Scholar
• Lin CS, Xin ZC, Deng CH, Ning H, Lin G, Lue TF. Defining adipose tissue-derived stem cells in tissue and in culture. Histol Histopathol. 2010;25:807–15.
   PubMed Web of Science ®Google Scholar
• Wagner W, Ho AD, Zenke M. Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B-Re. 2010;16:445–53.
   PubMed Web of Science ®Google Scholar
• Duggal S, Brinchmann JE. Importance of serum source for the in vitro replicative senescence of human bone marrow derived mesenchymal stem cells. J Cell Physiol. 2011;226:2908–15.
   PubMed Web of Science ®Google Scholar
• Lee WC, Rubin JP, Marra KG. Regulation of alpha-smooth muscle actin protein expression in adipose-derived stem cells. Cells Tissues Organs. 2006;183:80–6.
   PubMed Web of Science ®Google Scholar
• Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem. 1998;31:205–62.
   PubMedGoogle Scholar
• Suga H, Matsumoto D, Eto H, Inoue K, Aoi N, Kato H, . Functional implications of CD34 expression in human adipose-derived stem/progenitor cells. Stem Cells Dev. 2009; 18:1201–10.
   PubMed Web of Science ®Google Scholar